Universitätsklinikum Carl Gustav Carus Dresden

Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial (2022) González-Martín A, Desauw C, Heitz F, Cropet C, Gargiulo P, Berger R, Ochi H, et al. Journal article A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy (2022) Buettner FA, Winter S, Stuehler V, Rausch S, Hennenlotter J, Füssel S, Zastrow S, et al. Journal article Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation (2022) Kunadt D, Stasik S, Metzeler KH, Roellig C, Schliemann C, Greif PA, Spiekermann K, et al. Journal article Heterogeneous Development of b-Cell Populations in Diabetes-Resistant and-Susceptible Mice (2022) Gottmann P, Speckmann T, Stadion M, Zuljan E, Aga H, Sterr M, Buettner M, et al. Journal article Factors associated with long-term survival after failure a chimeric antigen receptor (CAR) T cell therapy for relapsed or refractory large B-cell lymphomas:a role for allogeneic stem cell transplantation? (2022) Derigs P, Bethge W, Holtick U, Von Tresckow B, Ayuk F, Penack O, Vucinic V, et al. Conference contribution 12-month trends in health-related quality of life after hospitalization - comparison of tumor entities (2022) Eichler M, Hornemann B, Hoenig K, Bergelt C, Faller H, Maatouk , Stein B, et al. Conference contribution Reproducibility of measurable residual disease detection by flow cytometry in acute myeloid leukemia (2022) Roehnert MA, Kramer M, Schadt J, Ensel P, Thiede C, Krause S, Buecklein V, et al. Conference contribution Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG (2022) Franklin C, Mohr P, Bluhm L, Grimmelmann I, Gutzmer R, Meier F, Garzarolli M, et al. Conference contribution Real-world clinical outcomes of pembrolizumab for advanced melanoma in the German ADOREG skin cancer registry (2022) Mohr P, Scherrer E, Alar V, Assaf C, Beissert S, Berking C, Eigentler T, et al. Conference contribution Therapy Management of the first Recurrence after adjuvant Therapy in Stage III: multicenter real-world Data (2022) Lodde G, Forschner A, Hassel JC, Wulfken LM, Meier F, Mohr P, Kaehler K, et al. Conference contribution